CJC1295 (No DAC) 5mg + IPA 5mg Peptide Australia

CJC1295 (No DAC) 5mg + Ipamorelin 5mg is a widely studied peptide combination valued in scientific research for its synergistic activity on growth hormone–related pathways. CJC1295 (No DAC), a tetrasubstituted analogue of GHRH (Growth Hormone-Releasing Hormone), is known for its short-acting profile, making it useful for researchers analysing pulsatile GH secretion. Ipamorelin, a selective ghrelin receptor (GHSR) agonist, is frequently examined for its targeted mechanism and minimal off-target interaction compared with older secretagogues.
When combined, these two compounds are often used in laboratory investigations aiming to study complementary pathways—CJC1295 (No DAC) stimulating the GHRH receptor and Ipamorelin stimulating the ghrelin receptor. This dual-pathway activation is of particular relevance to researchers exploring pulsatile hormone release, cellular signalling, and growth hormone modulation. The blend has become a preferred reference material in research environments for evaluating multi-pathway peptide interactions.
Our CJC1295 (No DAC) 5mg + IPA 5mg is produced to >99% purity (HPLC Verified), ensuring reliability, consistency, and suitability for controlled scientific applications. Each vial contains premium-grade lyophilised powder, offering long-term stability and easy reconstitution for laboratory workflows.